FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets

Rhea-AI Summary

FibroBiologics (Nasdaq: FBLG) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,691,147, titled “Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment.” The patent covers methods using fibroblasts to enhance engraftment, survival, and long-term function of transplanted pancreatic islets in Type 1 diabetes.

The technology describes fibroblast-based compositions that improve the microenvironment for transplanted islets, potentially increasing islet viability and donor tissue utilization. FibroBiologics, a clinical-stage biotech focused on fibroblast-based therapies, now holds 270+ issued and pending patents across multiple chronic disease areas.

Positive

• New U.S. patent 12,691,147 protecting fibroblast-based methods to improve islet engraftment in Type 1 diabetes
• Potential to increase donor tissue efficiency by improving survival and integration of transplanted islets
• Expanded IP portfolio with 270+ issued and pending patents across multiple chronic disease indications

Negative

• None.

Market Context

Historical patent news was followed by a 5.6% 24-hour move, while a manufacturing update preceded a ...

Analysis

Historical patent news was followed by a 5.6% 24-hour move, while a manufacturing update preceded a -3.26% reaction. The active S-3 resale registration adds a shareholder-supply consideration; clinical validation remains a watchpoint.

Key Figures

Patent number: 12,691,147 Patent issuance date: Aug. 11, 2026 Patents issued and pending: 270+ patents +1 more

4 metrics

Patent number 12,691,147 U.S. patent issued by the USPTO

Patent issuance date Aug. 11, 2026 U.S. patent grant announcement

Patents issued and pending 270+ patents Company-wide U.S. and international intellectual property portfolio

Affected population Millions of people People affected by Type 1 diabetes

Historical Context

5 past events · Latest: Aug 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 05	European patent grant	Positive	+5.6%	European patent expanded protection for fibroblast-based cartilage regeneration applications.
Jul 31	Earnings and trial update	Positive	+12.9%	Quarterly results, trial progress, and capital raises accompanied a 12.93% reaction.
Jul 09	Board appointment	Positive	+5.4%	Kathleen Rubins joined the board with scientific and genomics experience.
Jul 07	Manufacturing milestone	Positive	-3.3%	Third CYWC628 batch completed for the Phase 1/2 diabetic foot ulcer trial.
Jun 30	Conference participation	Neutral	+19.2%	Management participated in a cell therapy conference fireside chat.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news reactions were positive in four listed events, while the July 7 manufacturing update was followed by a negative reaction.

Key Terms

uspto, fibroblasts, islet engraftment, extracellular matrix proteins, +1 more

5 terms

uspto regulatory

"the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No."

United States Patent and Trademark Office (USPTO) is the federal agency that reviews and issues patents for inventions and registers trademarks for brand names and logos. For investors, USPTO decisions act like a gatekeeper for a company’s legal right to exclude competitors — similar to a property deed for ideas and brands — which can protect revenue, support pricing power, and affect a company’s long‑term value and risk profile.

fibroblasts medical

"methods utilizing fibroblasts to improve the engraftment and long-term function"

Fibroblasts are common cells in connective tissue that manufacture the structural proteins and fibers—like collagen—that form and repair the body's scaffolding, helping wounds heal and tissues hold their shape. For investors, fibroblasts matter because they are frequent targets or tools in drug development, regenerative medicine and safety testing: changes in their behavior can signal whether a therapy will work, cause side effects or enable new medical products, much like a construction crew determines the strength and finish of a building.

islet engraftment medical

"Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment"

The process by which transplanted pancreatic islet cells survive, connect with blood vessels and host tissue, and begin producing insulin in the recipient’s body. Think of it like planting young trees: engraftment is the period when the new plants must take root, get water and nutrients, and start growing on their own. For investors, engraftment is a key measure of whether an islet therapy or transplant achieves its intended medical effect and therefore influences clinical trial outcomes, regulatory decisions, and commercial potential.

extracellular matrix proteins medical

"Fibroblasts are known to produce extracellular matrix proteins, angiogenic factors"

Proteins in the extracellular matrix are the structural and signaling molecules that sit outside cells and form a biological 'scaffold'—think of them as the bricks, mortar, and wiring that hold tissues together and tell cells how to behave. They matter to investors because changes in these proteins are central to many diseases and wound healing, making them common targets for drugs, diagnostics, biomaterials, and regenerative therapies, and therefore important to company value, clinical outcomes, and regulatory review.

angiogenic factors medical

"produce extracellular matrix proteins, angiogenic factors, and trophic signals"

Proteins and signaling molecules that stimulate the growth of new blood vessels, playing key roles in wound healing, tumor growth, and various diseases. Investors care because drugs or diagnostics that block or boost these factors can change the course of treatments and market opportunities for oncology, ophthalmology, and vascular disorders — like controlling a city’s road-building crews to influence how neighborhoods develop and thrive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Patent has potential for applications beyond diabetes, including other cell and tissue transplantation procedures

HOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,691,147, entitled "Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment." The patent describes methods utilizing fibroblasts to improve the engraftment and long-term function of transplanted pancreatic islets, addressing one of the major challenges in islet transplantation.

Type 1 diabetes affects millions of people and is caused by autoimmune destruction of the insulin-producing beta cells of the pancreas. Transplantation of pancreatic islets remains the only established cell-based approach capable of restoring endogenous insulin production and, in some patients, achieving insulin independence. Adoption has been limited by a severe shortage of donor pancreases and the loss of transplanted islets due to poor engraftment.

The newly issued patent addresses the challenge by describing the use of fibroblasts to improve the microenvironment for transplanted islets. The patented methods encompass compositions and therapeutic approaches designed to increase islet viability following transplantation. Fibroblasts are known to produce extracellular matrix proteins, angiogenic factors, and trophic signals that may improve vascularization, reduce cell stress, and enhance survival of transplanted tissues.

"One of the greatest limitations facing islet transplantation is that many transplanted islets fail to survive the critical period immediately after implantation," said Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics. "If we can improve engraftment, each donor pancreas could potentially benefit more patients. Technologies that preserve transplanted islets may ultimately help expand access to curative therapies for patients living with Type 1 diabetes."

By improving the survival and integration of transplanted islets, the patented technology has the potential to increase the efficiency of donor tissue utilization. If fewer islets are required to achieve therapeutic benefit, more patients could potentially be treated using the same limited donor supply. The patent supports the potential for fibroblasts to play essential roles in tissue regeneration beyond their traditional structural functions.

For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the scope and strength of the Company's intellectual property portfolio, the potential indications for FibroBiologics' programs, including for diabetes and other cell and tissue transplantation procedures, FibroBiologics' research and development programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics' R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-granted-us-patent-covering-the-use-of-fibroblasts-to-enhance-survival-and-function-of-transplanted-insulin-producing-islets-302847500.html

SOURCE FibroBiologics, Inc.

FAQ

What patent did FibroBiologics (FBLG) receive for Type 1 diabetes treatment in August 2026?

FibroBiologics received U.S. Patent No. 12,691,147 covering fibroblast-based methods to improve islet engraftment in Type 1 diabetes. According to FibroBiologics, the patent protects methods and compositions that enhance survival and long-term function of transplanted pancreatic islets after transplantation.

How could FibroBiologics’ new fibroblast patent impact Type 1 diabetes patients and FBLG investors?

The patent may support more efficient islet transplantation by improving survival and engraftment of transplanted islets. According to FibroBiologics, this could allow each donor pancreas to benefit more patients, potentially expanding access to cell-based therapies and strengthening the company’s intellectual property position.

What technology is covered by FibroBiologics’ U.S. Patent No. 12,691,147 for FBLG?

The patent covers methods and compositions using fibroblasts to improve the microenvironment for transplanted pancreatic islets. According to FibroBiologics, fibroblasts produce extracellular matrix proteins, angiogenic factors, and trophic signals that may enhance vascularization, reduce cell stress, and support transplanted tissue survival.

Does the new FibroBiologics (FBLG) patent have applications beyond Type 1 diabetes?

Yes, the company notes the patent has potential applications beyond diabetes in other cell and tissue transplantation procedures. According to FibroBiologics, the fibroblast-based approach may help improve engraftment and survival of transplanted tissues generally, extending its relevance to broader regenerative medicine uses.

How many patents does FibroBiologics (Nasdaq: FBLG) report having after this new grant?

FibroBiologics reports holding more than 270 issued and pending patents in the United States and internationally. According to FibroBiologics, these patents span pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, cancer, and now islet engraftment in Type 1 diabetes.

What challenge in islet transplantation is FibroBiologics’ new patent intended to address for FBLG?

The patent targets poor engraftment and early loss of transplanted pancreatic islets, a major limitation in islet transplantation. According to FibroBiologics, many islets fail during the critical post-implantation period, and its fibroblast-based methods are designed to enhance islet viability and function.